FDA Advisors Split on Regimens for Breast, Prostate Cancers Sharon Worcester May 11, 2026

https://www.medscape.com/viewarticle/fda-advisors-split-regimens-breast-prostate-cancers-2026a1000f3j In its first meeting in 9 months, the FDA’s Oncologic Drugs Advisory Committee (ODAC) backed a novel regimen for certain patients with prostate cancer but voted against recommending a new treatment approach with an investigational drug for breast cancer.